Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name FLT3 over exp
Gene Variant Detail

FLT3 over exp (no effect)

Relevant Treatment Approaches FLT3 Inhibitor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 over exp hepatocellular carcinoma sensitive FLT3 Inhibitor Sorafenib Clinical Study Actionable In an observational clinical study, hepatocellular carcinoma patients harboring FLT3 overexpression treated with Nexavar (sorafenib) demonstrated improved overall survival (24.9 months (n=67)) when compared to patients with FLT3 overexpression who received a control treatment (10.0 months (n=49)) or patients with decreased FLT3 expression treated with Nexavar (sorafenib) (16.0 months (n=71)) (PMID: 32332018). 32332018
FLT3 over exp hepatocellular carcinoma sensitive FLT3 Inhibitor Sorafenib Preclinical - Pdx Actionable In a preclinical study, Nexavar (sorafenib) inhibited tumor growth and reduced the percentage of tumor cells expressing Ki-67 in patient-derived xenograft (PDX) models of hepatocellular carcinoma harboring FLT3 overexpression, but had no effect on tumor growth inhibition or Ki-67 expression compared to control treatments in PDX models of HCC harboring decreased FLT3 expression (PMID: 32332018). 32332018